MDMA and fenfluramine reduce L‐DOPA‐induced dyskinesia via indirect 5‐HT1A receptor stimulation
European Journal of Neuroscience May 1, 2006 Christopher Bishop, Jennifer L. Taylor, Donald M. Kuhn et al. 63 citations
In a rat model of Parkinson's disease, the serotonin-releasing drugs MDMA and fenfluramine reduced the abnormal involuntary movements (dyskinesia) caused by chronic L-DOPA treatment. This antidyskinetic effect was blocked by a drug that inhibits the serotonin 5-HT1A receptor, suggesting that these compounds work at least partly through that receptor. The findings indicate that boosting serotonin activity may help manage L-DOPA-induced dyskinesia without compromising the therapeutic benefit of L-DOPA.